~~ Session #1 - Life of a Drug ~~

We will survey the landscape of the issues and activities involved over the full lifecycle of drug development.

Speaker: Roger A. Hart, PhD
Roger Hart is a Scientific Director in Process Development and his work is focused on innovation within Amgen and with external academic collaborators. After working in biotechnology for almost 3 decades, he has participated in most aspects of the lifecycle of development for many modalities and numerous clinical and commercial drugs.

~~ Session #2 - Target Identification & Validation ~~

This lecture will cover the selection and validation of drug targets that serve as the basis for therapeutic development.

Speaker: John Ferbas, PhD
John Ferbas is a Scientific Director of Medical Sciences and Clinical Immunology. Dr. Ferbas received an M.S. (1989) and Ph.D. (1993) from the University of Pittsburgh School of Public Health and completed a post-doctoral fellowship at the UCLA School of Medicine in 1996. After service to the UCLA School of Medicine and Greater Los Angeles VA Medical Center as an Associate Professor, Dr. Ferbas joined Amgen (1999), where he held positions of increasing responsibility. He currently works in the Department of Medical Sciences the Director of the Cytometry Sciences Group, which represents an integrated core laboratory facility comprised of flow cytometers (analyzers and sorters), single and multiphoton microscopes and a mass cytometry (CyTOF) platform.

~~ Session #3 - Drug Discovery at Amgen: A Multi‐Modality Approach ~~

We will introduce Amgen’s broad toolkit of drug modalities and describe how we choose the “right” modality for drug discovery, focusing on biologic medicines.

Speaker: Roger A. Hart, PhD
Roger Hart is a Scientific Director in Process Development and his work is focused on innovation within Amgen and with external academic collaborators. After working in biotechnology for almost 3 decades, he has participated in most aspects of the lifecycle of development for many modalities and numerous clinical and commercial drugs.